Nura Bio Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
33
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$73.5M
- Investors
-
4
Nura Bio General Information
Description
Developer of transformative neuroprotective therapies designed to prevent and protect against neuronal loss and related neuroimmune dysregulation. The company's therapies specialize in the research and development of neuronal loss to preserve neurological function and restore the neuron-glia axis's function, enabling healthcare professionals to improve the nervous system's immune surveillance capacity in response to neurological injury.
Contact Information
Website
www.nurabio.comCorporate Office
- 171 Oyster Point Boulevard
- Suite 401
- South San Francisco, CA 94080
- United States
Corporate Office
- 171 Oyster Point Boulevard
- Suite 401
- South San Francisco, CA 94080
- United States
Nura Bio Timeline
Nura Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC (Series B) | 22-Jun-2026 | $73.5M | Completed | Clinical Trials - Phase 1 | ||
| 2. Later Stage VC | 17-Sep-2024 | Cancelled | Clinical Trials - Phase 1 | |||
| 1. Later Stage VC (Series A) | 18-Nov-2025 | $141M | $141M | Completed | Clinical Trials - Phase 1 |
Nura Bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Nura Bio Comparisons
Industry
Financing
Details
Nura Bio Competitors (3)
One of Nura Bio’s 3 competitors is NeuroNascent, a Venture Capital-Backed company based in Clarksville, MD.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| NeuroNascent | Venture Capital-Backed | Clarksville, MD | ||||
| Ovid Therapeutics | Formerly VC-backed | New York, NY | ||||
| Brainstorm Cell Therapeutics | Corporation | New York, NY |
Nura Bio Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Nura Bio Patents
Nura Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026226553-A1 | Covalent sarm1 inhibitors | Pending | 22-Apr-2025 | ||
| WO-2025207539-A1 | Sarm1 inhibitors | Pending | 25-Mar-2024 | ||
| WO-2025179205-A1 | Methods for the treatment of neurological disorders | Pending | 23-Feb-2024 | ||
| WO-2025117599-A1 | Bicyclic heteroaryl compounds as trem2 activators | Inactive | 30-Nov-2023 | ||
| EP-4798579-A1 | Covalent sarm1 inhibitors | Pending | 23-Oct-2023 | C07D403/12 |
Nura Bio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Nura Bio Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Euclidean Capital | Family Office | Minority | ||
| Samsara BioCapital | Venture Capital | Minority | ||
| Sanofi Ventures | Corporate Venture Capital | Minority | ||
| The Column Group | Venture Capital | Minority |
Nura Bio FAQs
-
When was Nura Bio founded?
Nura Bio was founded in 2018.
-
Where is Nura Bio headquartered?
Nura Bio is headquartered in South San Francisco, CA.
-
What is the size of Nura Bio?
Nura Bio has 33 total employees.
-
What industry is Nura Bio in?
Nura Bio’s primary industry is Drug Discovery.
-
Is Nura Bio a private or public company?
Nura Bio is a Private company.
-
What is Nura Bio’s current revenue?
The current revenue for Nura Bio is .
-
How much funding has Nura Bio raised over time?
Nura Bio has raised $214M.
-
Who are Nura Bio’s investors?
Euclidean Capital, Samsara BioCapital, Sanofi Ventures, and The Column Group have invested in Nura Bio.
-
Who are Nura Bio’s competitors?
NeuroNascent, Ovid Therapeutics, and Brainstorm Cell Therapeutics are competitors of Nura Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
